Trial Profile
Protein-Tyrosine Kinase Inhibitor (STI571) [imatinib] for Treatment of Patients With Ph+ Chronic Myeloid Leukemia Who Are Resistant to or Intolerant of alfa-Interferon. A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 07 Aug 2007 New trial record.